Tocagen (Tocagen) EBITDA Margin % : 0.00% (As of Mar. 2020)

View and export this data going back to 2017. Start your Free Trial

What is Tocagen EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tocagen's EBITDA for the three months ended in Mar. 2020 was $-9.47 Mil. Tocagen's Revenue for the three months ended in Mar. 2020 was $0.00 Mil. Therefore, Tocagen's EBITDA margin for the quarter that ended in Mar. 2020 was 0.00%.

Tocagen EBITDA Margin % Historical Data

The historical data trend for Tocagen's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tocagen EBITDA Margin % Chart

Tocagen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

EBITDA Margin %

-44,088.24

-63,612.24

-89,521.95

-242.30

-163,477.78

Tocagen Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
EBITDA Margin %	Get a 7-Day Free Trial													-179,044.44	-179,255.56	-183,755.56	-111,855.56	-

Competitive Comparison of Tocagen's EBITDA Margin %

For the Biotechnology subindustry, Tocagen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tocagen's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tocagen's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Tocagen's EBITDA Margin % falls into.

Tocagen EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Tocagen's EBITDA Margin % for the fiscal year that ended in Dec. 2019 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2019 )	/	Revenue (A: Dec. 2019 )
	=	-58.852	/	0.036
	=	-163,477.78 %

Tocagen's EBITDA Margin % for the quarter that ended in Mar. 2020 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2020 )	/	Revenue (Q: Mar. 2020 )
	=	-9.467	/	0
	=	%

Tocagen (NAS:TOCA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Tocagen EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Tocagen's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tocagen (Tocagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tocagen Inc (NAS:TOCA) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4242 Campus Point Court, Suite 500, San Diego, CA, USA, 92121

Website

http://www.tocagen.com

Tocagen Inc is a clinical-stage, cancer-selective gene therapy company. It is focused on developing product candidates designed to activate a patient's immune system against their own cancer from within. The company's cancer-selective gene therapy platform is built on retroviral replicating vectors, or RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Tocagen is developing product candidate, Toca 511 and Toca FC, for the treatment of recurrent high grade glioma, or HGG, a brain cancer with limited treatment options, low survival rates and, therefore, a significant unmet medical need. Geographically, the activities are carried out through United States.